Literature DB >> 32732219

Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge.

David Kernick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32732219      PMCID： PMC7384840          DOI： 10.3399/bjgp20X711833

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  7 in total

1.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 2.  Chronic migraine: epidemiology and disease burden.

Authors:  Aubrey N Manack; Dawn C Buse; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2011-02

Review 3.  Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.

Authors:  Nathaniel M Schuster; Alan M Rapoport
Journal:  Clin Neuropharmacol       Date:  2017 Jul/Aug       Impact factor: 1.592

4.  The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity.

Authors:  T J Steiner; A I Scher; W F Stewart; K Kolodner; J Liberman; R B Lipton
Journal:  Cephalalgia       Date:  2003-09       Impact factor: 6.292

Review 5.  Systematic review of migraine prophylaxis adherence and persistence.

Authors:  Zsolt Hepp; Lisa M Bloudek; Sepideh F Varon
Journal:  J Manag Care Pharm       Date:  2014-01

Review 6.  Blocking CGRP in migraine patients - a review of pros and cons.

Authors:  Marie Deen; Edvige Correnti; Katharina Kamm; Tim Kelderman; Laura Papetti; Eloisa Rubio-Beltrán; Simone Vigneri; Lars Edvinsson; Antoinette Maassen Van Den Brink
Journal:  J Headache Pain       Date:  2017-09-25       Impact factor: 7.277

7.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.